Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025

https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-february-2025

Ryan McArthur 14 February 2025 All news
  • ← CHARGE(E) DE PHARMACOVIGILANCE HYBRIDE
  • FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 – CTIS Training Programme – Module 01 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 – CTIS Training Programme – Module 01
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025
  • CHARGE(E) DE PHARMACOVIGILANCE HYBRIDE
Copyright © 2018 - Pharmya - Legal terms - Quality Policy